SBI Okasan Asset Management Co.Ltd. Acquires New Holdings in Arrowhead Pharmaceuticals, Inc. $ARWR

SBI Okasan Asset Management Co.Ltd. acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 36,500 shares of the biotechnology company’s stock, valued at approximately $2,541,000.

A number of other large investors have also recently added to or reduced their stakes in the business. CWM LLC grew its stake in Arrowhead Pharmaceuticals by 1.4% in the 4th quarter. CWM LLC now owns 12,347 shares of the biotechnology company’s stock valued at $820,000 after acquiring an additional 168 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Arrowhead Pharmaceuticals by 1.6% in the 4th quarter. PNC Financial Services Group Inc. now owns 11,102 shares of the biotechnology company’s stock valued at $737,000 after acquiring an additional 178 shares during the last quarter. HighTower Advisors LLC grew its stake in Arrowhead Pharmaceuticals by 0.3% in the 4th quarter. HighTower Advisors LLC now owns 133,229 shares of the biotechnology company’s stock valued at $8,845,000 after acquiring an additional 340 shares during the last quarter. Tsfg LLC acquired a new stake in Arrowhead Pharmaceuticals in the 4th quarter valued at about $25,000. Finally, Oregon Public Employees Retirement Fund grew its stake in Arrowhead Pharmaceuticals by 1.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 31,614 shares of the biotechnology company’s stock valued at $2,099,000 after acquiring an additional 430 shares during the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on ARWR shares. JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a research note on Friday, May 1st. They set an “overweight” rating and a $88.00 price target on the stock. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $78.00 to $100.00 in a report on Tuesday, April 21st. Sanford C. Bernstein lifted their price target on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. HC Wainwright reiterated a “buy” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a report on Wednesday, March 25th. Finally, Royal Bank Of Canada lifted their price target on shares of Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $87.80.

Arrowhead Pharmaceuticals Price Performance

ARWR opened at $79.05 on Friday. The company’s 50 day simple moving average is $69.14 and its 200 day simple moving average is $64.30. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $14.30 and a 1 year high of $82.26. The stock has a market capitalization of $11.13 billion, a PE ratio of -36.77 and a beta of 1.28.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business had revenue of $73.74 million for the quarter, compared to analysts’ expectations of $73.84 million. During the same period last year, the company earned $2.75 earnings per share. The company’s quarterly revenue was down 86.4% on a year-over-year basis. As a group, sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.98 EPS for the current year.

Insider Buying and Selling

In related news, CFO Daniel Joseph Apel sold 13,095 shares of the firm’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total value of $934,328.25. Following the sale, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at approximately $11,623,271.75. This trade represents a 7.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, April 23rd. The stock was sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 36,065 shares of company stock valued at $2,554,562. Insiders own 3.60% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.